Enlivex Therapeutics Ltd. (ENLV)
1.01
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
1.00
-0.83%
After-hours: Mar 28, 2025, 07:57 PM EDT
Company Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.
It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Enlivex Therapeutics Ltd.
| Country | IL |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Dr. Oren Hershkovitz Ph.D. |
Contact Details
Address: 14 Einstein Street Ness Ziona, IL | |
| Website | https://www.enlivex.com |
Stock Details
| Ticker Symbol | ENLV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001596812 |
| CUSIP Number | M4130Y106 |
| ISIN Number | IL0011319527 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
| Shachar Shlosberger CPA | Chief Financial Officer |
| Dr. Veronique Amor-Baroukh | Senior Director of Operations |
| Prof. Dror Mevorach M.D. | Founder & Scientific Advisor |
| Shai Novik M.B.A. | Executive Chairman |
| Sigal Arad | Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 6-K | Filing |
| Mar 04, 2025 | 6-K | Filing |
| Mar 03, 2025 | 6-K | Filing |
| Feb 18, 2025 | 6-K | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 11, 2024 | 6-K | Filing |
| Dec 03, 2024 | 6-K | Filing |
| Nov 29, 2024 | 6-K | Filing |
| Nov 20, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |